regulatory filings

Sanofi halts clinical trials and plans for regulatory filings with its investigational JAK2 inhibitor fedratinib

Paris, France, 21-11-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the decision to halt all clinical trials and cancel…

10 years ago